Mystery solved? Nektar chief says 'softening' in patient responses to bempeg was a CMC issue — spurring a rout
Nektar CEO Howard Robin says his top team has been puzzling out the reason why the response rates for their closely-watched drug NKTR-214 (bempegaldesleukin) “softened up” over time — with disastrous consequences. But the explanation didn’t satisfy anyone.
In fact, their stock $NKTR plunged close to 33% after the explanation, shredding more than $1.5 billion in market cap. And that’s not what Robin was looking for.
Basic subscription required
Unlock this story instantly and join 57,600+ biopharma pros reading Endpoints daily — and it's free.